| Original language | English (US) |
|---|---|
| Article number | e1001220 |
| Journal | PLoS medicine |
| Volume | 9 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2012 |
Funding
As part of a project sponsored by the US Attorney General Consumer and Prescriber Education Grant Program (funded by the Neurontin settlement ), we had the opportunity to bring together formulary committee chairs and participants from two public teaching hospitals and a university-based school of pharmacy. Our initiative, entitled the Formulary Leveraged Improved Prescribing (FLIP) Project was continued through the work of a US Agency for Healthcare Research and Quality–funded Center for Education and Research in Therapeutics . WG received grant funding from Abbott Labs- 2% FTE this year, Consulting with Walgreens (member of P&T Committee, ∼$5,000). JD had a summer student internship with Abbott Laboratories in Regulatory Affairs 2009–2010 7 k (2009) 8 k (2010). SW consulted for Abbott, Genentech, Primus. MK is a Consultant Pharmacist, Pharmacy and Therapeutics Committee, Catalyst Health Solutions, Inc, Rockville, MD. DT received unrestricted grant funding for research from Medco Health Solutions. BL consulted in last 3 years: Abbott (drug name confusion), Transcept. Stock ownership: Pharm I.R., Inc. (my own company, specializing in preventing and detecting drug name confusion errors). Expert witness testimony: Hernandez v. Schering (for Hernandez), Mason v. General Electric Company, et al. (for Mason). Grants received: Abbott (readability of MedGuides), Novartis (development of pharmacoepidemiologic methods), Ortho McNeil (safety of warfarin post orthopedic surgery), AHRQ (Tools for Optimizing Prescribing). Patents received: BLL Consulting, Inc. (related to preventing drug name confusions) Other: Board of Directors (unpaid) for Med-Errs, Inc. (drug name confusion).
ASJC Scopus subject areas
- General Medicine